FTC Issues Policy Statement on Orange Book Patent Gaming: Pharmaceutical Evergreening as Unfair Competition Under Section 5

The Federal Trade Commission issues a policy statement declaring that improper patent listings in the FDA’s ‘Orange Book’ (Approved Drug Products with Therapeutic Equivalence Evaluations) constitute potential unfair methods of competition under Section 5 of the FTC Act or unlawful …